Johnson, Patrick Connor http://orcid.org/0000-0002-3943-6608
Bailey, Abigail http://orcid.org/0000-0002-0238-6723
Ma, Qiufei http://orcid.org/0000-0003-4270-3487
Milloy, Neil http://orcid.org/0000-0002-6811-6312
Biondi, Emilia http://orcid.org/0009-0005-1983-8529
Quek, Ruben G. W. http://orcid.org/0000-0001-9602-3239
Weatherby, Sarah http://orcid.org/0009-0009-6750-2666
Barlow, Sophie http://orcid.org/0000-0001-5604-1360
Funding for this research was provided by:
Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA
Article History
Received: 23 February 2024
Accepted: 22 April 2024
First Online: 8 July 2024
Declarations
:
: P. Connor Johnson: Works at the Cancer Center, Massachusetts General Hospital, Boston, MA, USA, and a consultant for AstraZeneca Plc, Seagen, ADC Therapeutics, Incyte, Abbvie, BMS and Research Medically Home; Qiufei Ma: Employee of Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA, and has ownership interest in Regeneron Pharmaceuticals Inc.; Ruben G.W Quek: is an employee of Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA, and has ownership interest in Amgen Inc., Pfizer Inc., and Regeneron Pharmaceuticals Inc.; Abigail Bailey, Neil Milloy, and Emilia Biondi: Employees of Adelphi Real World and paid consultants to Regeneron Pharmaceuticals Inc in connection with the development of this manuscript.
: The survey was conducted in accordance with the Pearl Institutional Review Board (protocol number AG8980). Where patients provided data directly, they signed an informed consent form prior to participation in this study. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [] and Health Information Technology for Economic and Clinical Health Act legislation []. Physician participation was financially incentivized, with reimbursement upon survey completion according to fair market research rates.